Clinical utility of proton magnetic resonance spectroscopy in characterizing breast lesions

Rachel Katz-Brull, Philip T. Lavin, Robert E. Lenkinski

Research output: Contribution to journalArticle

233 Citations (Scopus)

Abstract

Proton magnetic resonance spectroscopy (1H MRS) of the breast has been proposed as an adjunct to the magnetic resonance imaging (MRI) examination to improve the specificity of distinguishing malignant breast tumors from benign breast tumors. In this review, we carry out a pooled analysis of the clinical breast 1H MRS studies undertaken to date to determine the factors that influence the diagnostic performance of this method. In total, five studies of breast 1H MRS from four independent centers around the world have been published to date. Altogether, 153 tumors were examined, 100 of which were confirmed histologically to be malignant and 53 of which were benign. The lesions presenting a detectable composite choline signal in their corresponding 1H MR spectra were diagnosed as malignant, whereas the lesions with no choline signal were diagnosed as benign. The sensitivity and specificity of breast 1H MRS for detecting breast cancer were 83% (95% confidence interval [CI] = 73% to 89%) and 85% (95% CI = 71% to 93%), respectively, and both values could be as high as 92% after technical exclusions. In a subgroup of 20 young women, the sensitivity and the specificity of the method approached 100%. The factors limiting the sensitivity of the examination were mainly technical. The use of the composite choline signal as a marker for malignancy in breast 1H MRS is a robust method with highly reliable interpretation, because it is based on the appearance of a single peak. The method is likely to provide even better results with technologic advances in breast MRS that lead to the improved detection of the composite choline signal.

Original languageEnglish (US)
Pages (from-to)1197-1203
Number of pages7
JournalJournal of the National Cancer Institute
Volume94
Issue number16
StatePublished - Aug 21 2002

Fingerprint

Breast
Choline
Breast Neoplasms
Confidence Intervals
Sensitivity and Specificity
Proton Magnetic Resonance Spectroscopy
Neoplasms
Magnetic Resonance Imaging

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Clinical utility of proton magnetic resonance spectroscopy in characterizing breast lesions. / Katz-Brull, Rachel; Lavin, Philip T.; Lenkinski, Robert E.

In: Journal of the National Cancer Institute, Vol. 94, No. 16, 21.08.2002, p. 1197-1203.

Research output: Contribution to journalArticle

@article{83bb829c7cc649fbb4a72d520948ae9d,
title = "Clinical utility of proton magnetic resonance spectroscopy in characterizing breast lesions",
abstract = "Proton magnetic resonance spectroscopy (1H MRS) of the breast has been proposed as an adjunct to the magnetic resonance imaging (MRI) examination to improve the specificity of distinguishing malignant breast tumors from benign breast tumors. In this review, we carry out a pooled analysis of the clinical breast 1H MRS studies undertaken to date to determine the factors that influence the diagnostic performance of this method. In total, five studies of breast 1H MRS from four independent centers around the world have been published to date. Altogether, 153 tumors were examined, 100 of which were confirmed histologically to be malignant and 53 of which were benign. The lesions presenting a detectable composite choline signal in their corresponding 1H MR spectra were diagnosed as malignant, whereas the lesions with no choline signal were diagnosed as benign. The sensitivity and specificity of breast 1H MRS for detecting breast cancer were 83{\%} (95{\%} confidence interval [CI] = 73{\%} to 89{\%}) and 85{\%} (95{\%} CI = 71{\%} to 93{\%}), respectively, and both values could be as high as 92{\%} after technical exclusions. In a subgroup of 20 young women, the sensitivity and the specificity of the method approached 100{\%}. The factors limiting the sensitivity of the examination were mainly technical. The use of the composite choline signal as a marker for malignancy in breast 1H MRS is a robust method with highly reliable interpretation, because it is based on the appearance of a single peak. The method is likely to provide even better results with technologic advances in breast MRS that lead to the improved detection of the composite choline signal.",
author = "Rachel Katz-Brull and Lavin, {Philip T.} and Lenkinski, {Robert E.}",
year = "2002",
month = "8",
day = "21",
language = "English (US)",
volume = "94",
pages = "1197--1203",
journal = "Journal of the National Cancer Institute",
issn = "0027-8874",
publisher = "Oxford University Press",
number = "16",

}

TY - JOUR

T1 - Clinical utility of proton magnetic resonance spectroscopy in characterizing breast lesions

AU - Katz-Brull, Rachel

AU - Lavin, Philip T.

AU - Lenkinski, Robert E.

PY - 2002/8/21

Y1 - 2002/8/21

N2 - Proton magnetic resonance spectroscopy (1H MRS) of the breast has been proposed as an adjunct to the magnetic resonance imaging (MRI) examination to improve the specificity of distinguishing malignant breast tumors from benign breast tumors. In this review, we carry out a pooled analysis of the clinical breast 1H MRS studies undertaken to date to determine the factors that influence the diagnostic performance of this method. In total, five studies of breast 1H MRS from four independent centers around the world have been published to date. Altogether, 153 tumors were examined, 100 of which were confirmed histologically to be malignant and 53 of which were benign. The lesions presenting a detectable composite choline signal in their corresponding 1H MR spectra were diagnosed as malignant, whereas the lesions with no choline signal were diagnosed as benign. The sensitivity and specificity of breast 1H MRS for detecting breast cancer were 83% (95% confidence interval [CI] = 73% to 89%) and 85% (95% CI = 71% to 93%), respectively, and both values could be as high as 92% after technical exclusions. In a subgroup of 20 young women, the sensitivity and the specificity of the method approached 100%. The factors limiting the sensitivity of the examination were mainly technical. The use of the composite choline signal as a marker for malignancy in breast 1H MRS is a robust method with highly reliable interpretation, because it is based on the appearance of a single peak. The method is likely to provide even better results with technologic advances in breast MRS that lead to the improved detection of the composite choline signal.

AB - Proton magnetic resonance spectroscopy (1H MRS) of the breast has been proposed as an adjunct to the magnetic resonance imaging (MRI) examination to improve the specificity of distinguishing malignant breast tumors from benign breast tumors. In this review, we carry out a pooled analysis of the clinical breast 1H MRS studies undertaken to date to determine the factors that influence the diagnostic performance of this method. In total, five studies of breast 1H MRS from four independent centers around the world have been published to date. Altogether, 153 tumors were examined, 100 of which were confirmed histologically to be malignant and 53 of which were benign. The lesions presenting a detectable composite choline signal in their corresponding 1H MR spectra were diagnosed as malignant, whereas the lesions with no choline signal were diagnosed as benign. The sensitivity and specificity of breast 1H MRS for detecting breast cancer were 83% (95% confidence interval [CI] = 73% to 89%) and 85% (95% CI = 71% to 93%), respectively, and both values could be as high as 92% after technical exclusions. In a subgroup of 20 young women, the sensitivity and the specificity of the method approached 100%. The factors limiting the sensitivity of the examination were mainly technical. The use of the composite choline signal as a marker for malignancy in breast 1H MRS is a robust method with highly reliable interpretation, because it is based on the appearance of a single peak. The method is likely to provide even better results with technologic advances in breast MRS that lead to the improved detection of the composite choline signal.

UR - http://www.scopus.com/inward/record.url?scp=0037151369&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037151369&partnerID=8YFLogxK

M3 - Article

VL - 94

SP - 1197

EP - 1203

JO - Journal of the National Cancer Institute

JF - Journal of the National Cancer Institute

SN - 0027-8874

IS - 16

ER -